ly-518674
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00133380)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
PPARA agonist
Compound failed to show an advantage over marketed fenofibrate in Ph2 trial. Also potential adverse effects on kidney function (http://www.firstwordpharma.com/node/110221#axzz3Oj1URprS). Developement on hold or discontinued?
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(Cn2nc(CCCc3ccc(OC(C)(C)C(=O)O)cc3)nc2O)cc1- Mol. weight
- 409.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL424133 ↗
Also known as
- kb-68984
- kb-68984
- ly518674
- ly518674
- ly518674
- ly 518674
- ly-518674
- ly-518674
- ly-518674
- ly-518674
- ly-674
- ly-674
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00374855 | Phase 2 | Sep 1, 2006 | Eli Lilly |
| NCT00327002 | Phase 2 | Jan 1, 2006 | Eli Lilly, University of Pennsylvania |
| NCT00116519 | Phase 2 | Jul 1, 2005 | Eli Lilly |
| NCT00133380 | Phase 2 | Jul 1, 2005 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 3 | 1 | 2005 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1